Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2

This publication has 8 references indexed in Scilit:

• Epstein‐Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways
  European Journal of Immunology, 1995
• Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein
  Molecular Immunology, 1995
• Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.
  The Journal of Experimental Medicine, 1993
• Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction
  Published by Elsevier ,1991
• gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral B lymphocytes
  FEBS Letters, 1986
• Tissue-specific phosphorylation of complement receptors CR1 and CR2.
  The Journal of Experimental Medicine, 1986
• gp140, a C3b‐binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4)
  European Journal of Immunology, 1985
• Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule
  European Journal of Immunology, 1985